Compare SON & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | DNTH |
|---|---|---|
| Founded | 1899 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.6B |
| IPO Year | 2014 | 2018 |
| Metric | SON | DNTH |
|---|---|---|
| Price | $49.56 | $86.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $60.13 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.3M | 422.6K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 510.30 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $7,518,753,000.00 | $2,036,000.00 |
| Revenue This Year | $0.10 | N/A |
| Revenue Next Year | $1.82 | $29.48 |
| P/E Ratio | $71.64 | ★ N/A |
| Revenue Growth | ★ 41.72 | N/A |
| 52 Week Low | $38.65 | $16.77 |
| 52 Week High | $58.44 | $96.50 |
| Indicator | SON | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 49.95 |
| Support Level | $46.73 | $82.00 |
| Resistance Level | $52.71 | $90.23 |
| Average True Range (ATR) | 1.32 | 4.58 |
| MACD | -0.02 | -0.20 |
| Stochastic Oscillator | 52.57 | 52.27 |
Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.